TrialJournal of the American Heart Association2020

First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction.

Dean J Kereiakes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.